OLYSIO

País: Nova Zelândia

Língua: inglês

Origem: Medsafe (Medicines Safety Authority)

Ingredientes ativos:

Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg

Disponível em:

Janssen-Cilag (New Zealand) Ltd

DCI (Denominação Comum Internacional):

Simeprevir sodium 154.4 mg (equivalent to simeprevir 150.0 mg)

Dosagem:

150 mg

Forma farmacêutica:

Capsule

Composição:

Active: Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg Excipient: Colloidal silicon dioxide Croscarmellose sodium Gelatin Lactose monohydrate Magnesium stearate Opacode black S-1-277002 Sodium laurilsulfate

Tipo de prescrição:

Prescription

Fabricado por:

Janssen Pharmaceutica NV

Indicações terapêuticas:

Olysio is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 or genotype 4 infection, in combination with other medicinal products for the treatment of CHC infection.

Resumo do produto:

Package - Contents - Shelf Life: Blister pack, PVC-PE-PVDC blister & Al push-through foil - 7 capsules - 24 months from date of manufacture stored at or below 30°C protect from light - Blister pack, PVC-PE-PVDC blister & Al push-through foil - 28 capsules - 24 months from date of manufacture stored at or below 30°C protect from light

Data de autorização:

2013-09-02